Core Viewpoint - The article discusses the implementation and sales performance of the newly established commercial insurance innovative drug directory, highlighting the concentration of sales in major cities and the challenges faced in expanding access to these drugs across the country [3][7]. Summary by Sections Sales Performance of New Drug Directories - As of January 20, 2026, 99 new drugs from the basic medical insurance directory have been sold in 12,198 designated medical institutions, while 14 drugs from the commercial insurance innovative drug directory have been sold in 223 institutions [3][4]. - Over 70% of the commercial insurance innovative drugs have recorded sales, with Alzheimer's disease treatments showing the highest penetration in the hospital market [4][5]. Specific Drug Sales Insights - The drug Lecanemab, developed by Eisai, has been sold in 158 institutions, while Eli Lilly's Donanemab has been recorded in 46 institutions [4]. - The number of patients with mild cognitive impairment or mild dementia due to Alzheimer's disease in China is projected to reach 17 million by 2024, indicating a broad patient base for these treatments [5]. Challenges in Rare Disease Drug Sales - Rare disease drugs face challenges due to their limited patient populations and the concentration of prescriptions in specialized hospitals, resulting in sparse sales data [5][6]. - For instance, Takeda's drug for short bowel syndrome has only been sold in one designated pharmacy in Shenzhen this year [5]. Market Access and Policy Implications - Five innovative drugs have yet to achieve sales in designated medical institutions, including CAR-T products priced between 990,000 to 1.3 million yuan per injection [6]. - The National Healthcare Security Administration has implemented a "three exclusions" policy to facilitate the entry of high-cost drugs into hospitals, but the transition from "entry" to "sales" remains complex due to various factors [6][7]. Regional Disparities in Sales - Sales of commercial insurance innovative drugs are still concentrated in major provinces like Beijing, Shanghai, Jiangsu, and Guangdong, with retail pharmacies accounting for less than 10% of sales [7][8]. - Some regions, such as Guangdong and Chongqing, have begun to support the prescription flow of commercial insurance innovative drugs, but broader implementation is needed [8].

Core Insights - The sales of commercial insurance innovative drugs remain concentrated in public hospitals in a few provinces such as Beijing and Shanghai, with a low proportion of sales through pharmacies [1][5] - As of January 20, 2023, 99 new basic medical insurance drugs were sold in 12,198 designated medical institutions, while 14 commercial insurance innovative drugs were sold in 223 institutions [1][5] Group 1: Sales Data and Trends - Over 70% of commercial insurance innovative drugs have recorded sales, but the specific sales performance varies among the 14 drugs [2] - Alzheimer's disease treatment drugs have the highest penetration in the hospital market, with drugs like Lecanemab and Donanemab achieving sales in 158 and 46 institutions respectively [2] - Multiple anti-tumor drugs are also penetrating the hospital market, with drugs like Ipilimumab and Lurbinectedin being sold in 35 and over 10 institutions respectively [2] Group 2: Challenges and Market Dynamics - Five innovative drugs have not yet formed sales in designated medical institutions, including CAR-T products priced between 990,000 to 1,300,000 yuan per injection [3] - The lack of sales does not imply that these drugs are not benefiting from the supportive policies for commercial insurance innovative drugs [3] - The transition from "hospital entry" to "sales" involves several factors, including physician prescriptions and patient payments, which may hinder the sales volume of these drugs [3] Group 3: Policy and Implementation - Most provinces have clarified that the entry of commercial insurance innovative drugs into hospitals will follow the guidelines of "nationally negotiated drugs" [4] - There is a push for the inclusion of all 19 drugs in the commercial insurance innovative drug directory into the procurement lists of hospitals, which may improve access for patients [4] - The integration of commercial insurance innovative drugs with the dual-channel policy of medical insurance is essential for enhancing confidence in the allocation of these drugs in hospitals [5]

Core Insights - The new medical insurance directory has entered a substantial implementation phase, with multiple innovative drugs, including Tislelizumab and Fuzhengzhu, being covered by insurance in various hospitals, indicating a reduction in access barriers for patients [1][3] - The adjustment includes 114 new drugs and introduces a dual insurance model, combining basic medical insurance with commercial health insurance, which opens payment channels for high-value drugs in oncology and rare diseases [1][3] Group 1: Innovative Drug Inclusion - The rapid inclusion of innovative drugs in the new medical insurance directory reflects increased support for "true innovation" with high clinical value, as evidenced by the inclusion of 124 unique products [3] - Notably, Tislelizumab, the first targeted drug for thyroid eye disease in China, was included in the insurance directory within a year of its market launch, filling a 70-year treatment gap [3] - Heng Rui Medicine emerged as a significant beneficiary, with 20 products and indications adjusted, including 10 new drugs, enhancing patient access to innovative therapies [3][4] Group 2: Commercial Health Insurance Impact - The introduction of the commercial health insurance directory provides a secondary market for high-value drugs, with price reductions ranging from 15% to 50%, which is less severe than the typical 60% cuts seen in basic medical insurance [6] - The inclusion of five CAR-T therapy products in the commercial insurance directory marks a significant breakthrough for high-priced treatments, which previously struggled to gain insurance coverage [5][6] - The dual-directory model creates a payment system that supports innovation while allowing for profitable pricing strategies for pharmaceutical companies [7][11] Group 3: Market Dynamics and Adjustments - The adjustment process also involved the removal of 29 drugs from the insurance directory, including Benarutide, which faced competition from more effective alternatives, highlighting the dynamic nature of the market [9][10] - The exit of certain drugs signals a shift towards prioritizing high-efficiency and urgently needed medications, enhancing the overall efficiency of the medical insurance fund [11] - Companies are encouraged to focus on true innovation rather than "me-too" products, aligning their research and development strategies with the evolving insurance landscape [5][11]

Core Insights - The new medical insurance directory has entered a substantial implementation phase, with multiple innovative drugs, including Tislelizumab and Fuzhengzhu, being covered by insurance in various hospitals, indicating a rapid reduction in access barriers for patients [1][3] - The adjustment includes 114 new drugs and introduces a commercial health insurance innovative drug directory for 2025, marking a significant shift towards a multi-tiered insurance payment system [1][3] Group 1: Innovative Drug Inclusion - The new medical insurance directory reflects increased support for "true innovation" with 124 unique products included, showcasing a strong emphasis on high clinical value [3][4] - Notable drugs like Tislelizumab, the first targeted therapy for thyroid eye disease, and Fuzhengzhu, a biological agent for psoriasis, have been rapidly integrated into the insurance system, filling long-standing treatment gaps [3][4] - Heng Rui Medicine is highlighted as a major beneficiary, with 20 products and indications adjusted, including 10 new drugs, enhancing patient access to innovative therapies [3][4] Group 2: Biotech Sector Impact - Companies like BeiGene, Innovent Biologics, and Kangfang Biotech are also benefiting from the new directory, accelerating their commercialization processes [4] - BeiGene is the only company with two products included in the first commercial insurance innovative drug directory, addressing unmet needs in cholangiocarcinoma and neuroblastoma [4] - Innovent Biologics has expanded its offerings to 12 innovative drugs under the new directory, creating a robust product matrix [4] Group 3: Shift in R&D Strategies - The introduction of the commercial insurance innovative drug directory is seen as a solution to the payment challenges faced by high-value innovative drugs, encouraging companies to focus on true innovation rather than me-too products [5][6] - The directory allows for a second market for high-priced therapies, with price reductions between 15% and 50%, which is less severe than the typical cuts seen in basic insurance [6][7] - This dual-directory model is expected to drive pharmaceutical companies to align their R&D strategies with real-world clinical needs, particularly in oncology and rare diseases [7][9] Group 4: Drug Exclusions - The adjustment also involved the removal of 29 drugs from the insurance directory, including Benalutide injection, which faced competition from more effective alternatives [8][9] - This "one in, one out" approach aims to enhance the efficiency of insurance fund usage by prioritizing high-demand and effective medications [9]

Core Insights - The new medical insurance directory has entered a substantial implementation phase, with several innovative drugs, including Tislelizumab and Fuzhengzhu, being prescribed under insurance in various hospitals, indicating a reduction in access barriers for patients [1] - The adjustment includes 114 new drugs and introduces a commercial health insurance directory for innovative drugs, marking a significant shift towards a multi-tiered insurance system [1][5] - The rapid inclusion of innovative drugs in the insurance directory reflects increased support for "true innovation" with high clinical value [5] Group 1: New Drug Inclusion - The new medical insurance directory has added 124 unique products, including Tislelizumab, the first targeted drug for thyroid eye disease, and Fuzhengzhu, a biological agent for psoriasis [5] - Heng Rui Medicine is a major beneficiary, with 20 products and indications adjusted, including 10 new drugs entering the directory for the first time [5][6] - Other biotech companies like BeiGene and Innovent Biologics have also benefited, with multiple products included in the new directory, enhancing their commercialization prospects [7] Group 2: Commercial Health Insurance Directory - The introduction of the commercial health insurance directory provides a secondary market for high-value innovative drugs, with price reductions ranging from 15% to 50%, which is less severe than the basic insurance cuts [9] - The directory aims to improve accessibility for high-priced drugs while ensuring adequate returns for pharmaceutical companies [9] - Notable CAR-T therapies have been included in the commercial directory, overcoming previous barriers to entry, with prices for these therapies exceeding 1 million yuan [8][10] Group 3: Market Dynamics and Drug Exits - The adjustment process has also seen the removal of 29 drugs from the insurance directory, including Benarutide, which faced competition from more effective alternatives [12][14] - The dynamic adjustment mechanism emphasizes the need for drugs to demonstrate clinical value, reinforcing a "can enter, can exit" policy [14] - Companies are encouraged to shift from "me-too" products to genuine innovations, focusing on high-value areas such as oncology and rare diseases [10][14]

Core Viewpoint - The new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) and the first Commercial Health Insurance Innovative Drug Catalog (2025) will be implemented nationwide starting January 1, 2026, adding 114 new drugs to the basic insurance catalog and 19 to the commercial insurance catalog, aimed at enhancing drug accessibility and supporting innovation in the pharmaceutical industry [1][2]. Group 1: Drug Catalog Adjustments - The updated basic medical insurance catalog includes 114 new drugs, with significant representation from oncology (36 drugs), chronic diseases like diabetes (12 drugs), anti-infective drugs (13 drugs), and rare diseases (10 drugs), while 29 drugs were removed due to better alternatives [2]. - The total number of drugs in the national medical insurance catalog has increased to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines [2]. - The adjustment reflects a comprehensive coverage of diseases, addressing clinical pain points and improving access to previously unavailable treatments for conditions like triple-negative breast cancer and pancreatic cancer [2]. Group 2: Policy Implementation and Access - To address the issue of new drugs being listed but not available in hospitals, the policy mandates that all designated medical institutions must include new drugs in their procurement catalogs by the end of February 2026, with provisions for temporary green channels if necessary [3]. - Negotiated drugs will not be subject to administrative restrictions such as "one drug, two regulations" or overall medical insurance caps, allowing for more flexible access [3]. Group 3: Support for Innovative Drugs - Among the new drugs added to the basic medical insurance catalog, 50 are classified as category 1 innovative drugs, with an overall success rate of 88%, up from 76% in 2024, indicating a shift towards strategic purchasing and value-based reimbursement [4]. - The catalog includes both domestic innovative products and foreign original research products, enhancing the diversity of available treatments [4]. Group 4: Commercial Health Insurance Innovations - The newly established commercial health insurance innovative drug catalog includes 19 drugs, focusing on high-innovation, clinically valuable treatments that fill gaps in existing coverage, such as CAR-T cell therapies and treatments for rare diseases prevalent in children [7]. - This catalog complements the basic medical insurance, allowing pharmaceutical companies to expand their market reach while reducing the financial burden on patients [7]. Group 5: Industry Impact and Future Directions - The policy signals strong government support for independent innovation and encourages pharmaceutical companies to invest more in original and differentiated research and development [8]. - The National Medical Insurance Bureau plans to refine policies and enhance management to ensure effective implementation of the drug catalogs, ultimately improving the clinical medication needs of insured individuals [8].

Core Insights - The new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) and the first Commercial Health Insurance Innovative Drug Catalog (2025) will be implemented nationwide starting January 1, 2026, adding 114 new drugs to the basic insurance catalog and 19 to the commercial insurance catalog [1][2]. Group 1: Drug Catalog Adjustments - The updated basic medical insurance catalog includes 114 new drugs, with significant representation from oncology (36 drugs), chronic diseases (12 drugs), anti-infectives (13 drugs), and rare diseases (10 drugs) [2]. - The total number of drugs in the national medical insurance catalog has increased to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines [2]. - The adjustment aims to address clinical treatment gaps and enhance drug accessibility for patients, particularly for previously hard-to-treat conditions like triple-negative breast cancer and pancreatic cancer [2][4]. Group 2: Policy Implementation - A combination of policies will ensure that newly added drugs are available in hospitals by February 2026, including the establishment of temporary green channels for procurement [3]. - Negotiated drugs will not be subject to administrative restrictions such as "one product, two regulations" or overall medical insurance caps, allowing for more flexible access [3]. Group 3: Support for Innovation - Among the new drugs, 50 are classified as first-class innovative drugs, with an overall success rate of 88%, up from 76% in 2024, indicating a shift towards strategic purchasing and value-based reimbursement [4]. - The inclusion of both domestic and foreign innovative products in the catalog reflects a commitment to enhancing drug accessibility and supporting pharmaceutical innovation [4]. Group 4: Commercial Health Insurance - The newly established commercial health insurance innovative drug catalog includes 19 drugs, focusing on high-innovation, clinically valuable treatments that complement the basic medical insurance offerings [7]. - The catalog features advanced therapies such as CAR-T cell treatments and drugs for rare diseases, which are expected to reduce patient financial burdens and enhance market attractiveness for pharmaceutical companies [7][8]. Group 5: Future Directions - The policy signals strong government support for independent innovation and aims to encourage pharmaceutical companies to invest more in original and differentiated research and development [8]. - The National Medical Insurance Administration plans to refine policies and strengthen management to ensure the effective implementation of the drug catalogs, enhancing public access to necessary medications [8].

Core Insights - The new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) and the first Commercial Health Insurance Innovative Drug Catalog (2025) will be implemented nationwide starting January 1, 2026, adding 114 new drugs to the basic insurance catalog and 19 to the commercial insurance catalog [1][2] Group 1: Drug Inclusion and Coverage - The updated basic medical insurance catalog includes 114 new drugs, with significant representation from oncology (36 drugs), chronic diseases (12 drugs), anti-infectives (13 drugs), and rare diseases (10 drugs) [2] - The total number of drugs in the national medical insurance catalog will increase to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines [2] - The inclusion of innovative drugs addresses clinical gaps, such as previously untreatable conditions like triple-negative breast cancer and pancreatic cancer, enhancing patient access to necessary treatments [2][4] Group 2: Policy Implementation and Access - To address the issue of newly included drugs not being available in hospitals, the policy mandates that all designated medical institutions must include new drugs in their procurement catalogs by the end of February 2026, with provisions for temporary green channels if necessary [3] - Negotiated drugs will not be subject to administrative restrictions like "one drug, two regulations" or total medical insurance expenditure limits, facilitating quicker access to high-value innovative drugs [3] Group 3: Innovation and Market Dynamics - Among the newly added drugs, 50 are classified as first-class innovative drugs, with an overall success rate of 88%, up from 76% in 2024, indicating a shift towards strategic purchasing and value-based reimbursement in the healthcare system [4][5] - The 2025 catalog includes both domestic innovative products and foreign original research products, reflecting a commitment to enhancing drug accessibility and supporting innovation [4] Group 4: Commercial Health Insurance Innovations - The first Commercial Health Insurance Innovative Drug Catalog includes 19 drugs, primarily high-innovation treatments for conditions like neuroblastoma and Gaucher disease, which are often prevalent in children [7] - The commercial insurance catalog complements the basic medical insurance, allowing pharmaceutical companies to expand their market presence while reducing patient financial burdens [7][8] Group 5: Future Directions and Industry Impact - The policy signals strong government support for independent innovation and aims to ensure that the value of innovations is recognized and rewarded, encouraging pharmaceutical companies to invest more in original and differentiated research [8] - The National Medical Insurance Bureau plans to refine policies and enhance management to ensure the effective implementation of the drug catalogs, ultimately improving the clinical medication experience for insured individuals [8]

Core Insights - The new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) and the first Commercial Health Insurance Innovative Drug Catalog (2025) will be implemented nationwide starting January 1, 2026, adding 114 new drugs to the basic insurance catalog and 19 to the commercial insurance catalog [1][6] Group 1: Drug Catalog Adjustments - The adjustment of the National Medical Insurance Drug Catalog adheres to principles of supporting genuine innovation and differentiated innovation, aiming to meet diverse medication needs and enhance accessibility to high-value innovative drugs [1][2] - The updated catalog includes 36 cancer drugs, 12 chronic disease medications, 13 anti-infection drugs, and 10 rare disease treatments, increasing the total number of drugs in the catalog to 3,253 [1][2] - The inclusion of 50 first-class innovative drugs reflects a significant increase in the success rate of new drug approvals, rising from 76% in 2024 to 88% in 2025 [3][4] Group 2: Policy Implementation and Impact - The National Medical Insurance Bureau has adjusted the drug catalog for eight consecutive years, adding a total of 949 new drugs, with expenditures exceeding 460 billion yuan and sales exceeding 600 billion yuan during the negotiation period [2][3] - New policies require medical institutions to include newly added drugs in their procurement lists by the end of February 2026, addressing the issue of drugs being listed but not available in hospitals [2][3] Group 3: Commercial Health Insurance Innovative Drug Catalog - The first Commercial Health Insurance Innovative Drug Catalog includes 19 drugs, primarily high-innovation and clinically valuable treatments, which complement the basic medical insurance offerings [6][7] - The catalog features advanced therapies such as CAR-T cell treatments and bispecific antibodies, targeting rare diseases prevalent in children, thus expanding market opportunities for pharmaceutical companies [6][7] Group 4: Industry Response and Future Outlook - The policy sends a clear signal of government support for independent innovation, encouraging pharmaceutical companies to invest more in original and differentiated research and development [7] - The National Medical Insurance Bureau plans to refine policies and enhance management to ensure the effective implementation of the drug catalogs, ultimately improving the clinical medication experience for insured individuals [7]

Core Insights - The new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) and the first Commercial Health Insurance Innovative Drug Catalog (2025) will be implemented nationwide starting January 1, 2026, adding 114 new drugs to the basic insurance catalog and 19 to the commercial insurance catalog [1][6]. Summary by Sections Drug Inclusion and Coverage Expansion - The basic medical insurance catalog includes 114 new drugs, with 36 for cancer, 12 for chronic diseases like diabetes, 13 for anti-infection, and 10 for rare diseases, while 29 drugs were removed due to better alternatives [1]. - The total number of drugs in the national medical insurance catalog will increase to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines [1]. Innovation and Market Impact - The inclusion of 50 first-class innovative drugs reflects a significant increase in the success rate of new drug approvals to 88%, up from 76% in 2024, indicating a shift towards strategic and value-based purchasing in medical insurance [3][4]. - Notable foreign innovative products, such as Novartis' and Johnson & Johnson's drugs, have also been included, highlighting the commitment to enhancing drug accessibility [3]. Policy Measures for Drug Accessibility - To address the issue of newly included drugs not being available in hospitals, the policy mandates that medical institutions must include these drugs in their procurement lists by the end of February 2026 and allows for temporary green channels if necessary [2]. - Negotiated drugs will not be subject to administrative restrictions, ensuring better access for patients [2]. Commercial Health Insurance Innovations - The first commercial health insurance innovative drug catalog includes 19 drugs, focusing on high-innovation, clinically valuable treatments that exceed basic insurance coverage, thus addressing gaps in clinical drug availability [6]. - The drugs listed are primarily from the 2021-2025 period and include advanced therapies for rare diseases, enhancing market appeal and patient access [6]. Industry Response and Future Directions - The policy signals strong government support for independent innovation, encouraging pharmaceutical companies to invest more in original and differentiated research and development [7]. - The National Medical Insurance Bureau plans to refine policies and strengthen management to ensure the effective implementation of the new drug catalogs, ultimately improving public access to necessary medications [7].